Patents by Inventor Songchun Jiang

Songchun Jiang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MACROCYCLIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASE
    Publication number: 20220071971
    Abstract: The invention relates to heterocyclic compounds of the formula (I), in which all of the variables are as defined in the specification; capable of modulating the activity of CFTR. The invention further provides a method for manufacturing compounds of the invention, and its therapeutic uses. The invention further provides methods to their preparation, to their medical use, in particular to their use in the treatment and management of diseases or disorders including Cystic fibrosis and related disorders.
    Type: Application
    Filed: December 18, 2019
    Publication date: March 10, 2022
    Inventors: Mihai Azimioara, Badry Bursulaya, Songchun Jiang, Casey Jacob Nelson MATHISON, Victor Ivanovich NIKULIN, Truc Ngoc NGUYEN, Barun OKRAM, Sejal PATEL, Dean Paul PHILLIPS, Lewis WHITEHEAD, Baogen WU, Shanshan YAN, Xuefeng ZHU
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS
    Publication number: 20210101902
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Application
    Filed: December 16, 2020
    Publication date: April 8, 2021
    Inventors: Phillip ALPER, Jonathan DEANE, Songchun JIANG, Tao JIANG, Thomas KNOEPFEL, Pierre-Yves MICHELLYS, Daniel MUTNICK, Wei PEI, Peter SYKA, Guobao ZHANG, Yi ZHANG
  • Compounds and compositions as inhibitors of endosomal toll-like receptors
    Patent number: 10954233
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Grant
    Filed: September 6, 2017
    Date of Patent: March 23, 2021
    Assignee: NOVARTIS AG
    Inventors: Phillip Alper, Jonathan Deane, Songchun Jiang, Tao Jiang, Thomas Knoepfel, Pierre-Yves Michellys, Daniel Mutnick, Wei Pei, Peter Syka, Guobao Zhang, Yi Zhang
  • COMPOUNDS AND COMPOSITIONS AS INHIBITORS OF ENDOSOMAL TOLL-LIKE RECEPTORS
    Publication number: 20190211009
    Abstract: The invention disclosed herein relates to 4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridinyl compounds and 4,5,6,7-tetrahydro-2H-pyrazolo[4,3-c]pyridinyl compounds of Formula (A), pharmaceutical compositions comprising such compounds and the use of such compounds in the treatment of autoimmune diseases.
    Type: Application
    Filed: September 6, 2017
    Publication date: July 11, 2019
    Inventors: Phillip Alper, Jonathan DEANE, Songchun JIANG, Tao JIANG, Thomas KNOEPFEL, Pierre-Yves MICHELLYS, Daniel MUTNICK, Wei PEI, Peter SYKA, Guobao ZHANG, YI ZHANG
  • COMPOUNDS AND THERAPEUTICAL USE THEREOF
    Publication number: 20170050937
    Abstract: Disclosed are 4-arylamino-quinazolines and analogs thereof effective as activators of caspases and inducers of apoptosis. The compounds of this invention are useful in the treatment of a variety of clinical conditions in which uncontrolled growth and spread of abnormal cells occurs.
    Type: Application
    Filed: March 25, 2016
    Publication date: February 23, 2017
    Inventors: Sui Xiong Cai, Nilantha Sudath Sirisoma, Azra Pervin, John A. Drewe, Shailaja Kasibhatla, Songchun Jiang, Hong Zhang, Chris Pleiman, Vijay Baichwal, John Manfredi, Leena Bhoite
  • Compounds and compositions for modulating EGFR Activity
    Patent number: 9440957
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Grant
    Filed: June 5, 2013
    Date of Patent: September 13, 2016
    Assignee: Novartis AG
    Inventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya, Songchun Jiang
  • Compounds and Compositions for Modulating EGFR Activity
    Publication number: 20150197505
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Application
    Filed: June 5, 2013
    Publication date: July 16, 2015
    Applicant: IRM LLC, A Delaware Limited Liability Company
    Inventors: Gerald Lelais, Robert Epple, Thomas H. Marsilje, III, Pierre-Yves Michellys, Matthew McNeill, Yun Long, Wenshuo Lu, Bei Chen, Badry Bursulaya Bursulaya, Songchun Jiang
  • Compounds and Compositions for Modulating EGFR Activity
    Publication number: 20150152083
    Abstract: The invention provides compounds and pharmaceutical compositions thereof, which are useful for modulating EGFR activity, as well as methods for using such compounds to treat, ameliorate or prevent a condition associated with abnormal or deregulated EGFR activity.
    Type: Application
    Filed: June 5, 2013
    Publication date: June 4, 2015
    Applicant: IRM LLC, A Delaware Limited Liability Company
    Inventors: Gerald Lelais, Robert Epple, Pierre-Yves Michellys, Badry Bursulaya, Songchun Jiang, Thomas H. Marsilje III, Matthew MCneill
  • Compounds and compositions as kinase inhibitors
    Patent number: 8859574
    Abstract: The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: July 23, 2013
    Date of Patent: October 14, 2014
    Assignee: IRM LLC
    Inventors: Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Xiaohui He, Christian Cho-Hua Lee, Songchun Jiang, Kunyong Yang
  • FLUOROPHENYL BICYCLIC HETEROARYL COMPOUNDS
    Publication number: 20130338152
    Abstract: The present invention provides a compound the invention, and its use as a IGF-1R inhibitor. The present invention further provides a combination of pharmacologically active agents and a pharmaceutical composition.
    Type: Application
    Filed: March 8, 2012
    Publication date: December 19, 2013
    Applicants: IRM LLC, NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Clive McCarthy, Pierre-Yves Michellys, Stefan Stutz
  • COMPOUNDS AND COMPOSITIONS AS KINASE INHIBITORS
    Publication number: 20130310361
    Abstract: The invention provides novel pyrimidine derivatives and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-1R) or analplastic lymphoma kinase (ALK).
    Type: Application
    Filed: July 23, 2013
    Publication date: November 21, 2013
    Inventors: Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Xiaohui He, Christian Cho-Hua Lee, Songchun Jiang, Kunyong Yang
  • Pyrimidine derivatives as kinase inhibitors
    Patent number: 8519129
    Abstract: The invention provides novel pyrimidine derivatives of formula I and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: August 27, 2013
    Assignee: IRM LLC
    Inventors: Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Xiaohui He, Christian Cho-Hua Lee, Songchun Jiang, Kunyong Yang
  • Pyrimidine derivatives as kinase inhibitors
    Patent number: 8445505
    Abstract: The invention provides novel pyrimidine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
    Type: Grant
    Filed: June 24, 2009
    Date of Patent: May 21, 2013
    Assignee: IRM LLC
    Inventors: Thomas H. Marsilje, III, Wenshuo Lu, Bei Chen, Xiaohui He, Songchun Jiang, Kunyong Yang
  • Benzene-fused 6-membered oxygen-containing heterocyclic derivatives of bicyclic heteroaryls
    Publication number: 20120289501
    Abstract: The invention relates to new derivatives of formula I, wherein the substituents are as defined in the specification; to processes for the preparation of such derivatives; pharmaceutical compositions comprising such derivatives; such derivatives as a medicament; such derivatives for the treatment of a proliferative disease.
    Type: Application
    Filed: November 23, 2010
    Publication date: November 15, 2012
    Applicant: NOVARTIS AG
    Inventors: Bei Chen, Robin Alec Fairhurst, Andreas Floersheimer, Pascal Furet, Songchun Jiang, Wenshuo Lu, Thomas H. Marsilje, III, Andrea Vaupel
  • COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20120196844
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: March 16, 2012
    Publication date: August 2, 2012
    Applicant: IRM LLC
    Inventors: Phillip B. Alper, Mihai Azimioara, Christopher Cow, Robert Epple, Songchun Jiang, Gerald lelais, Pierre-Yves Michellys, Daniel Mutnick, Victor Nikulin, Lucas Westcott-Baker
  • Compounds and compositions as modulators of GPR119 activity
    Patent number: 8153635
    Abstract: The invention provides compounds of Formula I: wherein A, L, m, q, Q, R1, R2, R3, R4 and R5 are defined in the Summary of the Invention. The invention further provides for pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Grant
    Filed: September 4, 2008
    Date of Patent: April 10, 2012
    Assignee: IRM LLC
    Inventors: Phillip B. Alper, Mihai Azimioara, Christopher Cow, Robert Epple, Songchun Jiang, Gerald Lelais, Pierre-Yves Michellys, Daniel Mutnick, Victor Nikulin
  • [4,5?]Bipyrimidinyl-6,4?-diamine derivatives as protein kinase inhibitors
    Patent number: 8026243
    Abstract: The invention provides a novel class of compounds of the Formula I: in which the symbols have the meanings given in the description and claims, to pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with abnormal or deregulated kinase activity, particularly diseases or disorders that involve abnormal activation of FGFR3 kinase.
    Type: Grant
    Filed: July 10, 2007
    Date of Patent: September 27, 2011
    Assignee: Novartis AG
    Inventors: Pamela A. Albaugh, Yun He, Songchun Jiang, Pingda Ren, Xia Wang, Xing Wang, Yongping Xie
  • COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20110224185
    Abstract: The invention provides compounds, pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: May 23, 2011
    Publication date: September 15, 2011
    Inventors: Phillip B. Alper, Mihai Azimioara, Christopher Cow, Robert Epple, Songchun Jiang, Gerald Lelais, Pierre-Yves Michellys, Daniel Mutnick, Victor Nikulin, Lucas Westcott-Baker
  • COMPOUNDS AND COMPOSITIONS AS MODULATORS OF GPR119 ACTIVITY
    Publication number: 20110190263
    Abstract: The invention provides compounds of Formula (I): pharmaceutical compositions comprising such compounds and methods of using such compounds to treat or prevent diseases or disorders associated with the activity of GPR119.
    Type: Application
    Filed: February 20, 2009
    Publication date: August 4, 2011
    Applicant: IRM LLC
    Inventors: Mihai Azimioara, Christopher Cow, Robert Epple, Songchun Jiang, Gerald Lelais, Baogen Wu, Daniel Mutnick
  • PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS
    Publication number: 20110112096
    Abstract: The invention provides novel pyrimidine derivatives of formula (I) and pharmaceutical compositions thereof, and methods for using such compounds. For example, the pyrimidine derivatives of the invention may be used to treat, ameliorate or prevent a condition which responds to inhibition of insulin-like growth factor (IGF-IR) or analplastic lymphoma kinase (ALK).
    Type: Application
    Filed: June 24, 2009
    Publication date: May 12, 2011
    Applicant: ITM LLC
    Inventors: Thomas H. Marsilje, Wenshuo Lu, Bei Chen, Xiaohui He, Songchun Jiang, Kunyong Yang